1. Pink Sheet

Closing The Books On Aduhelm: Congressional Report Leaves US FDA To Move Forward

 
• By Michael McCaughan

A Congressional report on the US FDA approval of Biogen/Eisai’s Aduhelm generated another round of negative headlines for the agency – and rubbed salt in the wounds of a commercial disaster for the sponsors. But it probably could not have turned out better for FDA and the drug review climate overall.

closing the book on Aduhelm
The House report on Aduhelm is probably headed straight for the shelf. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, House report images

It is hard to imagine a quieter end to the House Energy & Commerce Committee’s investigation into the US Food & Drug Administration’s handling of the review of Biogen, Inc./Eisai Co., Ltd.’s Alzheimer’s therapy Aduhelm (aducanumab-avwa).

The Congressional inquiry was launched with much fanfare two weeks after Aduhelm was approved in June 2021, amid headlines warning...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.